SCIENTEX is a hands-on advisory, transition & executive management firm, fully dedicated to healthcare players : biotech, pharma, medtech, CRO, primary & secondary investment funds, R&D and governmental agencies.
SCIENTEX is covering mainly financing & business development matters, on sell & buy side: from seed capital to public offerings & follow-on, M&A, business development & licensing, R&D partnering
SCIENTEX has developed 4 products & services in order to boost all corporate activities, by leveraging the track record of its two founders (+100 deals since 1999 including financing, R&D partnering, BD & licensing, IPOs, M&A on both sell & buy sides & 30 missions since 2006 & +26 board member position since 1999) :
SCIENTEX's associates are structured to work 60% more (2430 hours/year) than the 1529 hours, average working time in Europe. Thanks to its low cost fees, SCIENTEX will allow its clients to reduce their labor costs compared to FTE. Each of the 2 associates of SCIENTEX are limiting their supports to 2 clients max in parallel in order to guarantee their full intensive, full time , fully dedicated and home office & commuting based supports, without any outsourcing.